No Data
No Data
Fosun Pharma Receives Offers for Share Alternative Offer Related to Henlius Merger Offer
Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) received offers for a potential share alternative offer in relation to its merger offer for Shanghai Henlius Biotech (HKG:2696),
BofA Merrill Lynch is bullish! Raised the target price of Fosun Pharma's (02196) H shares to 17 yuan, accelerating innovation and transformation to achieve results.
Recently, international investment bank Morgan Stanley released its latest research report and raised the target price for Fosun Pharma's H shares from the original HKD 16 to HKD 17, indicating a potential increase of over 25% from the current H share price. It also maintained a 'shareholding' rating for Fosun Pharma, and predicted that the compound annual growth rates of the company's pharmaceutical, equipment, and hospital businesses' revenue from 2023 to 2025 will reach 8%, 13%, and 10%, respectively. This forecast reflects the strong growth momentum of core pharmaceutical sales, particularly in biosimilars and innovative drugs.
Fosun Pharma Advances Towards Henlius Privatization
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Fosun Pharma (02196) spent approximately 10.6336 million yuan to buy back 0.482 million A shares on July 9.
Fosun Pharma (02196) announced that it will invest approximately 10.6336 million yuan (RMB) on July 9, 2024...
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
No Data